BayBio Pantheon Ceremony Celebrates Bay Area’s Record Number of New Treatments

SOUTH SAN FRANCISCO, Calif. – Nov. 1, 2012 — More than one quarter of FDA approvals in 2012 were developed by Bay Area companies, and BayBio will recognize the people and companies that dedicated themselves to bringing these new treatments to patients at its annual Pantheon Awards Ceremony on November 1 in San Francisco.

“BayBio’s Pantheon Ceremony celebrates the unprecedented proportion of new treatments developed here in Northern California,” said BayBio President and CEO Gail Maderis. “We applaud the people and companies who have dedicated their efforts to restore patients to health.

Capping a banner year in Bay Area life sciences commercialization, BayBio will present DiNA Awards to the industry’s current leaders and inaugurate three Lifetime Achievement Award recipients into the BayBio Pantheon.

David Goeddel, Ph.D., Edward Penhoet, Ph.D., and Pablo Valenzuela, Ph.D., will receive Lifetime Achievement Awards for their leadership and ingenious creativity that has shaped the Bay Area life science cluster. From their individual scientific discoveries to executive leadership to investments in numerous startups, these three men helped create the climate that has allowed Bay Area life sciences to lead the world in developing new treatments. Goeddel pioneered genetic engineering of bacteria that enabled development of Genentech’s first recombinant protein therapeutics. Penhoet and Valenzuela paved the way for Chiron’s recombinant vaccine business. These two companies created the climate that has allowed Bay Area life sciences to lead the world in developing new treatments.

Leading executives, researchers and dedicated individuals will receive DiNA Awards for treatments and technologies benefiting patients. The 2012 DiNA Award recipients are:

About BayBio
BayBio brings together the collective strength and experience of the world’s most innovative and productive life science cluster, helping companies grow, connect and advocate to solve some of humanity’s most pressing challenges. Online at